Online citations, reference lists, and bibliographies.
← Back to Search

ERCC1 As A Biological Marker Guiding Management In Malignant Pleural Mesothelioma.

Y. Cihan, A. Ozturk, Alaettin Arslan, K. Deniz, Munevver Baran, H. Karaca
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND To determine prognostic value of excision repair cross-complementation 1 (ERCC1) in patients with malignant pleural mesothelioma (MPM). MATERIALS AND METHODS The study included 60 patients with MPM who were diagnosed and treated in the Radiation Oncology Department of Kayseri Teaching Hospital and Medical Oncology Department of Erciyes University, Medicine School between 2005 and 2013. By using immunohistochemical methods, ERCC1 expression in biopsy specimens was evaluated. We retrospectively assessed whether there is a correlation between ERCC1 and response to anti-neoplastic therapy or survival. RESULTS There were 50 men and 10 women with median age of 62 years (range: 39-83). Histological type was epithelial mesothelioma in the majority of the cases (85%), most commonly presenting in stage four. Of the cases, 20 (33%) received radiotherapy, 60 (%100) received first-line chemotherapy and 15 (%25) received second-line chemotherapy. In the assessment after therapy, it was found that there was partial response in 12 cases (20%), stable disease in 19 cases (31.4%) and progression in 25 cases (41.7%). ERCC1 was positive in 43% of the cases. Mean OS was 11.7 months and mean DFS was 9.5 months in ERCC1-positive cases regardless of therapy, while they were 19.2 months and 17.1 months in ERCC1-negative cases, respectively. The difference was found to be significant (p<0.05). In univariate analysis, stage, comorbidity, response to treatment and ERCC1 expression were found to be significantly associated with OS (p=0.083; p=0.043; p=0.041; p=0.050). In multivariate analysis, response to treatment remained to be significant for OS (p=0.005). In univariate and multivariate analyses, response to treatment and ERCC1 were found to be significantly associated with DFS (p=0.049; p=0.041). CONCLUSIONS ERCC1 was identified as poor prognostic factor in patients with MPM.
This paper references
10.7314/APJCP.2013.14.9.5507
DNA repair capacity in peripheral blood lymphocytes predicts efficacy of platinum-based chemotherapy in patients with gastric cancer.
Y. Zhang (2013)
10.1016/j.mrfmmm.2011.01.001
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
M. Betti (2011)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.1016/J.LUNGCAN.2007.10.014
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
K. Lee (2008)
10.1016/j.urolonc.2012.10.010
ERCC1 and its role in tumor pathogenesis and progression.
Shailendra Kapoor (2013)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1097/JTO.0b013e318233d6a9
Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival
Z. G. Zimling (2012)
10.7314/APJCP.2013.14.12.7203
Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
F. Li (2013)
10.1097/JTO.0b013e3181ffe909
Pharmacogenetic and Germline Prognostic Markers of Lung Cancer
A. Horgan (2011)
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
V. Pagan (2006)
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Yan Li (2011)
Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer.
M. Ozkan (2010)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1056/NEJMOA060570
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
K. Olaussen (2006)
10.7314/APJCP.2012.13.6.2583
Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy.
Z. Zhang (2012)
10.7314/APJCP.2013.14.1.145
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Xiandong Li (2013)
10.1093/ANNONC/MDL300
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
P. Ceppi (2006)
10.1016/j.lungcan.2011.03.016
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
M. Joerger (2011)
10.1378/CHEST.122.6.2224
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
10.1378/CHEST.127.3.978
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.
G. Simon (2005)
10.1158/1078-0432.CCR-07-2238
Platinum Resistance: The Role of DNA Repair Pathways
L. Martin (2008)
10.1038/sj.onc.1205803
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
G. Pfeifer (2002)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar